Enzon said that the study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.
Ivan Horak, president of research and development at Enzon, said: “We are excited about the potential PEG-SN38 can have in the pediatric setting. Given PEG-SN38’s safety profile and the unmet medical need in pediatric patients, this compound may play an important role in the future treatment of children who have cancer.”